Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Therapy 104

Therapy Legalization Chronic Pain DEA 104

Veriheal

JUNE 23, 2022

A Pennsylvania state trooper had noticed the issue with Murphy’s headlight, which he was en route to receiving an estimate to fix. While in MA, he utilized cannabis which was legal under state law, in order to find relief from chronic pain and PTSD.

Consumption 105

Consumption Legalization Concentrates Patients 105

MedicalJane

JUNE 29, 2018

Pennsylvania’s neighboring state, Maryland , has a much shorter list of qualifying medical conditions: cachexia, anorexia, wasting syndrome, severe pain or nausea or persistent muscle spasms, seizures, glaucoma, PTSD, and chronic pain. State laws will set the guidelines for qualifying a practitioner.

Patients 83

Patients Legalization Conditions Treatment 83

The Joint Blog

JUNE 4, 2021

Schedule I drugs like heroin, Lysergic Acid Diethylamide (LSD), and ecstasy are strictly regulated by the Federal Government but Marijuana has be made an exception in some states. Marijuana is also classified as a Schedule I drug but it has been given the approval for medical and recreational at some state levels. Improve weight gain.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Canna Law Blog

MARCH 4, 2020

With respect to ketamine infusion therapy (which is the prime time attraction of ketamine clinics), the medical research based promise is for treatment of chronic neuropathic pain, chronic pain (instead of opioids), and various medication-resistant mental health disorders, including depression, bi-polar disorder, and PTSD (among others).

Legalization 55

Legalization Therapy Chronic Pain DEA 55

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. After the hearing concludes, the administrative law judge will compile a report based on the testimony given.

DEA 97

DEA Policy Chronic Pain Marijuana 97